BlueTree Ventures

By playing in the under-served inland mid-Atlantic market, we readily compete for the best opportunities

Our management team has more than 70 years of combined experience in IT, hardware, and life sciences

• 06 OCT PEPTILOGICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B STUDY OF PLG0206 FOR PERIPROSTHETIC JOINT INFECTION PITTSBURGH, PA – October 6, 2022 — Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 tr Read More PITTSBURGH, PA – October 6, 2022 — Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced it has dosed its first patient with PLG0206 in the LOGIC-1 tr
• 30 SEP Disrupters: Jonathan Steckbeck The CEO, founder and president of Peptilogics is changing the game for the peptide medicine space with a promising pipeline and a disruptive discovery platform
• Published Sept
• 6, 2022 Meagan ParrishLead Editor Permissio Read More The CEO, founder and president of Peptilogics is changing the game for the peptide medicine space with a promising pipeline and a disruptive discovery platform Published Sept 6, 2022 Meagan ParrishLead Editor Permissio
• 25 JUL PEPTILOGICS RECEIVES FDA FAST TRACK DESIGNATION FOR PLG0206, AN INVESTIGATIONAL PEPTIDE THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF PERIPROSTHETIC JOINT INFECTION PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of periprosthetic joint infection Pittsburgh, PA [ July 19, 2022]: Peptilogics, a biotech company engineering peptide therapeutics Read More PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment of periprosthetic joint infection Pittsburgh, PA [ July 19, 2022]: Peptilogics, a biotech company engineering peptide therapeutics